Microbiota in digestive cancers: our new partner?
- 17 August 2017
- journal article
- review article
- Published by Oxford University Press (OUP) in Carcinogenesis
- Vol. 38 (12) , 1157-1166
Abstract
Evolution led to an essential symbiotic relationship between the host and commensal microbiota, regulating physiological functions including inflammation and immunity. This equilibrium can be disturbed by environmental factors such as lifestyle, diet or antibiotic pressure, contributing to create a dysbiosis. There is much evidence about the gut microbiota’s contribution to carcinogenesis, involving pro-inflammatory and immunosuppressive signals. At the same time, it seems to be increasingly clear that commensal microbes can modulate cancer therapy efficacy and safety, in particular, innovating treatments as immune checkpoint inhibitors. In this review, we discuss how the microbiota can promote digestive tract carcinogenesis, responsiveness to cancer therapeutics and cancer-associated complications.Keywords
This publication has 89 references indexed in Scilit:
- Global burden of cancers attributable to infections in 2012: a synthetic analysisThe Lancet Global Health, 2016
- Pathobiology of Helicobacter pylori–Induced Gastric CancerGastroenterology, 2016
- Cancer and the microbiotaScience, 2015
- Gut microbiome and anticancer immune response: really hot Sh*t!Cell Death & Differentiation, 2014
- Lack of microbiota reduces innate responses and enhances adaptive immunity againstListeria monocytogenesinfectionEuropean Journal of Immunology, 2014
- Innate immune recognition of the microbiota promotes host-microbial symbiosisNature Immunology, 2013
- A human gut microbial gene catalogue established by metagenomic sequencingNature, 2010
- The Human Microbiome ProjectNature, 2007
- Immunoproliferative Small Intestinal Disease Associated withCampylobacter jejuniNew England Journal of Medicine, 2004
- A Bacterial Toxin That Controls Cell Cycle Progression as a Deoxyribonuclease I-Like ProteinScience, 2000